查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916721

個人化癌症治療市場預測至2032年：按產品、癌症類型、技術、最終用戶和地區分類的全球分析

Personalized Oncology Market Forecasts to 2032 - Global Analysis By Product (Diagnostic Tests, Targeted Therapies, Companion Diagnostics, Biomarkers, Personalized Vaccines and Other Products), Cancer Type, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，預計到 2025 年，全球個人化癌症治療市場價值將達到 1,183.8 億美元，到 2032 年將達到 2,277.8 億美元，在預測期內的複合年成長率為 9.8%。

個人化癌症治療是一種基於精準醫學的癌症治療方法，它根據個體獨特的基因、分子和細胞特徵來客製化治療方法。透過分析腫瘤生物標記、基因突變和患者特異性特徵，臨床醫生可以選擇最有效的標靶治療、免疫療法或聯合治療，同時最大限度地減少副作用。這種策略可以改善治療效果，提高病人安全性，並支持早期發現和監測。個人化癌症治療標誌著從傳統的「一刀切」式治療模式轉向精準醫學的轉變，為更有效、以患者為中心的癌症治療帶來了希望。

全球癌症負擔日益加重

全球癌症發生率和盛行率的不斷上升是推動個人化癌症治療市場發展的主要因素。隨著人口老化、生活方式改變和環境因素導致癌症病例增加，人們對精準、高效且個人化的治療方案的需求也日益成長。個人化癌症治療能夠根據腫瘤的基因和分子特徵進行標靶治療，從而改善臨床療效和患者生活品質。日益加重的癌症負擔正推動全球醫療保健系統加強對先進診斷技術、基因組學和治療創新領域的投資。

醫療成本不斷上漲

個人化癌症治療的高昂費用是限制市場成長的主要阻礙因素。先進的診斷程序、基因組分析和標靶治療通常需要大量資金，限制了患者的就醫途徑，尤其是在中低收入地區。此外，漫長的治療方案和專業的醫療基礎設施也加重了醫療服務提供者的經濟負擔。這些高支出可能會減緩治療方法的普及，限制患者的就醫範圍，並造成治療缺口。

基因組學和分子診斷的進展

基因組學和分子診斷技術的快速發展為市場帶來了巨大的成長機會。次世代定序、液態生物檢體和生物標記分析等創新技術能夠實現早期檢測和精準治療方案的選擇。這些技術進步有助於制定個人化治療策略並最大限度地減少副作用。人工智慧 (AI) 與生物資訊學的融合將進一步提升預測能力，提高個人化癌症治療的效率和臨床療效，並拓展其在全球各類癌症類型和醫療保健系統中的應用潛力。

監管和核准的挑戰

監管的複雜性和嚴格的核准流程對市場構成重大威脅。新型治療方法和診斷工具必須經過嚴格的臨床試驗，並符合各種國際監管標準，這可能會延緩產品上市。不同地區的核准時間差異，以及生物標記驅動療法指南的不斷更新，都給研發人員和投資者帶來了不確定性。這些挑戰增加了研發成本，並可能延緩產品上市，即使這些創新治療方法具有臨床前景和變革癌症治療的潛力，患者也可能無法及時獲得治療。

新冠疫情的感染疾病

新冠疫情擾亂了個人化癌症治療市場，導致全球範圍內的臨床試驗、常規診斷和擇期癌症治療均出現延誤。醫療資源被調配用於應對疫情，影響了病患招募、治療實施和檢查室運作。供應鏈中斷進一步影響了診斷試劑盒和治療藥物的供應。然而，疫情也加速了遠端醫療、遠距監測和數位健康工具的普及，凸顯了建構具有韌性的醫療基礎設施的必要性。

預計在預測期內，基因組學將佔據最大的市場規模。

由於基因組學在識別基因突變和腫瘤特徵方面發揮關鍵作用，預計在預測期內，基因組學領域將佔據最大的市場佔有率。包括次世代定序和全基因組分析在內的基因組學技術，為精準治療方法的選擇和治療監測提供了至關重要的資訊。隨著臨床醫生越來越依賴基因數據指南標靶治療和免疫治療，對基因組學服務的需求正在蓬勃發展。持續的技術創新和定序成本的下降，使基因組學成為推動整體市場發展的關鍵因素。

預計在預測期內，診斷檢查室細分市場將呈現最高的複合年成長率。

由於對專業檢測服務的需求不斷成長，預計診斷檢查室領域在預測期內將實現最高成長率。這些檢查室發揮著至關重要的作用，包括進行生物標記分析以指導標靶治療的選擇。精準醫療意識的不斷提高，以及對先進診斷基礎設施的投資，正在推動市場擴張。癌症發生率的上升和早期檢測策略的普及進一步刺激了需求，使診斷檢查室成為個人化癌症治療生態系統中快速成長且不可或缺的一部分。

比最大的地區

亞太地區預計將在預測期內保持最大的市場佔有率，這主要得益於該地區癌症發病率的上升、醫療基礎設施的不斷完善以及對先進癌症治療投資的持續成長。精準醫療意識的提高、政府為加強癌症治療而採取的措施以及基因組和分子診斷技術的普及，都推動了市場成長。此外，大規模的患者群體以及標靶治療的日益普及，使亞太地區成為個人化癌症治療創新和臨床應用的關鍵市場中心。

年複合成長率最高的地區

在預測期內，北美預計將實現最高的複合年成長率，這主要得益於其先進的醫療基礎設施和對創新治療方法的早期應用。該地區受益於基因組學、生物標記發現和精準醫療計畫的巨額投資，以及能夠加快核准的法規結構。患者意識的提高、尖端診斷技術的廣泛應用以及製藥公司與研究機構之間的密切合作，正在推動市場成長，使北美成為個人化癌症治療的領先中心。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，提供主要國家的市場估算和預測以及複合年成長率（註：可行性需確認）。
  • 競爭標竿分析
    • 根據主要參與者的產品系列、地理覆蓋範圍和策略聯盟進行基準分析

目錄

第1章執行摘要

第2章 前言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球個人化癌症治療市場（依產品分類）

  • 診斷測試
  • 標靶治療
  • 伴隨診斷
  • 生物標記
  • 個人化疫苗
  • 其他

6. 全球個人化癌症治療市場（依癌症類型分類）

  • 乳癌
  • 肺癌
  • 大腸直腸癌
  • 攝護腺癌
  • 血癌
  • 其他

7. 全球個人化癌症治療市場（依技術分類）

  • 基因組學
  • 蛋白質體學
  • 次世代定序（NGS）
  • 生物資訊學

8. 全球個人化癌症治療市場（依最終用戶分類）

  • 醫院和診所
  • 診斷檢查室
  • 研究所
  • 藥局和零售店
  • 其他

9. 全球個人化癌症治療市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章：重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章 企業概況

  • Roche
  • Novartis
  • Pfizer
  • Merck &Co.
  • AstraZeneca
  • Bristol-Myers Squibb
  • Eli Lilly
  • Amgen
  • Bayer
  • AbbVie
  • Johnson &Johnson
  • Takeda
  • Illumina
  • Qiagen
  • Tempus AI
Product Code: SMRC33294

According to Stratistics MRC, the Global Personalized Oncology Market is accounted for $118.38 billion in 2025 and is expected to reach $227.78 billion by 2032 growing at a CAGR of 9.8% during the forecast period. Personalized oncology is a precision-driven approach to cancer treatment that tailors therapies based on an individual's unique genetic, molecular, and cellular profile. By analyzing tumor biomarkers, gene mutations, and patient-specific characteristics, it enables clinicians to select targeted therapies, immunotherapies, or combination treatments that are most effective while minimizing adverse effects. This strategy improves treatment outcomes, enhances patient safety, and supports early detection and monitoring. Personalized oncology represents a shift from traditional one-size-fits-all approaches toward precision medicine, offering hope for more effective, patient-centric cancer care.

Market Dynamics:

Driver:

Rising Global Cancer Burden

The increasing incidence and prevalence of cancer worldwide is a key driver for the personalized oncology market. As cancer cases rise due to aging populations, lifestyle changes, and environmental factors, there is a growing demand for precise, effective, and individualized treatment options. Personalized oncology enables targeted therapies based on genetic and molecular tumor profiles, improving clinical outcomes and patient quality of life. This rising cancer burden fuels investments in advanced diagnostics, genomics, and therapeutic innovations across global healthcare systems.

Restraint:

High Treatment Costs

The high costs associated with personalized oncology therapies present a significant restraint to market growth. Advanced diagnostic procedures, genomic sequencing, and targeted treatments often require substantial financial resources, limiting accessibility for patients, particularly in low- and middle-income regions. Additionally, prolonged treatment regimens and specialized healthcare infrastructure increase economic burdens on healthcare providers. These high expenditures can slow adoption, reduce patient reach, and create disparities in treatment availability.

Opportunity:

Advances in Genomics & Molecular Diagnostics

Rapid advancements in genomics and molecular diagnostics offer substantial growth opportunities for the market. Innovations such as next-generation sequencing, liquid biopsies, and biomarker profiling enable early detection and precise therapy selection. These technological developments allow for tailored treatment strategies and minimizing adverse effects. The integration of artificial intelligence and bioinformatics further enhances predictive capabilities, making personalized oncology more efficient and clinically impactful, while expanding its potential across diverse cancer types and global healthcare systems.

Threat:

Regulatory & Approval Challenges

Regulatory complexities and stringent approval processes pose a critical threat to the market. New therapies and diagnostic tools must undergo rigorous clinical trials and comply with diverse international regulatory standards, which can delay market entry. Variations in approval timelines across regions, coupled with evolving guidelines for biomarker-driven treatments, create uncertainty for developers and investors. Such challenges increase development costs and may slow adoption, hindering timely patient access to innovative therapies despite their clinical promise and potential to transform cancer care.

Covid-19 Impact:

The Covid-19 pandemic disrupted the personalized oncology market by delaying clinical trials, routine diagnostics, and elective cancer treatments worldwide. Healthcare resources were redirected toward pandemic management, affecting patient enrollment, therapy administration, and laboratory operations. Supply chain interruptions further impacted the availability of diagnostic kits and therapeutic agents. However, the pandemic also accelerated the adoption of telemedicine, remote monitoring, and digital health tools, highlighting the need for resilient healthcare infrastructure.

The genomics segment is expected to be the largest during the forecast period

The genomics segment is expected to account for the largest market share during the forecast period, due to its pivotal role in identifying genetic mutations and tumor profiles. Genomic technologies, including next-generation sequencing and whole-genome analysis, provide critical insights for precision therapy selection and treatment monitoring. As clinicians increasingly rely on genetic data to guide targeted therapies and immunotherapies, demand for genomic services is surging. Continuous innovation, combined with declining sequencing costs, positions the genomics as a central growth driver across markets.

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the diagnostic laboratories segment is predicted to witness the highest growth rate, due to rising need for specialized testing services. These laboratories perform critical functions, including biomarker analysis, which guide targeted therapy selection. Growing awareness of precision medicine, coupled with investments in advanced diagnostic infrastructure fuels market expansion. The increasing prevalence of cancer and adoption of early detection strategies further amplify demand, establishing diagnostic laboratories as a rapidly growing and indispensable component of the personalized oncology ecosystem.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to region's growing cancer prevalence, expanding healthcare infrastructure, and increasing investments in advanced oncology treatments. Rising awareness of precision medicine, government initiatives to enhance cancer care, and improving accessibility to genomic and molecular diagnostics contribute to market growth. Additionally, the presence of a large patient population, coupled with increasing adoption of targeted therapies, positions Asia Pacific as a significant market hub for personalized oncology innovations and clinical applications.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to advanced healthcare infrastructure and early adoption of innovative therapies. The region benefits from significant investments in genomics, biomarker discovery, and precision medicine programs, supported by regulatory frameworks that facilitate rapid approvals. High patient awareness, widespread use of cutting-edge diagnostic technologies, and strong collaborations between pharmaceutical companies and research institutions drive market growth, making North America a leading hub for personalized oncology.

Key players in the market

Some of the key players in Personalized Oncology Market include Roche, Novartis, Pfizer, Merck & Co., AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Amgen, Bayer, AbbVie, Johnson & Johnson, Takeda, Illumina, Qiagen and Tempus AI.

Key Developments:

In January 2026, Pfizer and Cartography Biosciences forged a multi-year collaboration to use Cartography's ATLAS and SUMMIT discovery platforms to pinpoint tumor-selective antigens for future cancer therapies, with Pfizer funding research and holding development and commercialization rights.

In December 2025, Pfizer struck an exclusive global collaboration and license deal with YaoPharma to develop, manufacture, and commercialize YP05002, an oral GLP 1 weight management agent, advancing its cardiometabolic pipeline with upfront and milestone payments and potential worldwide impact.

Products Covered:

  • Diagnostic Tests
  • Targeted Therapies
  • Companion Diagnostics
  • Biomarkers
  • Personalized Vaccines
  • Other Products

Cancer Types Covered:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Hematological Cancers
  • Other Cancer Types

Technologies Covered:

  • Genomics
  • Proteomics
  • Next-Generation Sequencing (NGS)
  • Bioinformatics

End Users Covered:

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmacies & Retail
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Personalized Oncology Market, By Product

  • 5.1 Introduction
  • 5.2 Diagnostic Tests
  • 5.3 Targeted Therapies
  • 5.4 Companion Diagnostics
  • 5.5 Biomarkers
  • 5.6 Personalized Vaccines
  • 5.7 Other Products

6 Global Personalized Oncology Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Lung Cancer
  • 6.4 Colorectal Cancer
  • 6.5 Prostate Cancer
  • 6.6 Hematological Cancers
  • 6.7 Other Cancer Types

7 Global Personalized Oncology Market, By Technology

  • 7.1 Introduction
  • 7.2 Genomics
  • 7.3 Proteomics
  • 7.4 Next-Generation Sequencing (NGS)
  • 7.5 Bioinformatics

8 Global Personalized Oncology Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals & Clinics
  • 8.3 Diagnostic Laboratories
  • 8.4 Research Institutes
  • 8.5 Pharmacies & Retail
  • 8.6 Other End Users

9 Global Personalized Oncology Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Roche
  • 11.2 Novartis
  • 11.3 Pfizer
  • 11.4 Merck & Co.
  • 11.5 AstraZeneca
  • 11.6 Bristol-Myers Squibb
  • 11.7 Eli Lilly
  • 11.8 Amgen
  • 11.9 Bayer
  • 11.10 AbbVie
  • 11.11 Johnson & Johnson
  • 11.12 Takeda
  • 11.13 Illumina
  • 11.14 Qiagen
  • 11.15 Tempus AI

List of Tables

  • Table 1 Global Personalized Oncology Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Personalized Oncology Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Personalized Oncology Market Outlook, By Diagnostic Tests (2024-2032) ($MN)
  • Table 4 Global Personalized Oncology Market Outlook, By Targeted Therapies (2024-2032) ($MN)
  • Table 5 Global Personalized Oncology Market Outlook, By Companion Diagnostics (2024-2032) ($MN)
  • Table 6 Global Personalized Oncology Market Outlook, By Biomarkers (2024-2032) ($MN)
  • Table 7 Global Personalized Oncology Market Outlook, By Personalized Vaccines (2024-2032) ($MN)
  • Table 8 Global Personalized Oncology Market Outlook, By Other Products (2024-2032) ($MN)
  • Table 9 Global Personalized Oncology Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 10 Global Personalized Oncology Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 11 Global Personalized Oncology Market Outlook, By Lung Cancer (2024-2032) ($MN)
  • Table 12 Global Personalized Oncology Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 13 Global Personalized Oncology Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 14 Global Personalized Oncology Market Outlook, By Hematological Cancers (2024-2032) ($MN)
  • Table 15 Global Personalized Oncology Market Outlook, By Other Cancer Types (2024-2032) ($MN)
  • Table 16 Global Personalized Oncology Market Outlook, By Technology (2024-2032) ($MN)
  • Table 17 Global Personalized Oncology Market Outlook, By Genomics (2024-2032) ($MN)
  • Table 18 Global Personalized Oncology Market Outlook, By Proteomics (2024-2032) ($MN)
  • Table 19 Global Personalized Oncology Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 20 Global Personalized Oncology Market Outlook, By Bioinformatics (2024-2032) ($MN)
  • Table 21 Global Personalized Oncology Market Outlook, By End User (2024-2032) ($MN)
  • Table 22 Global Personalized Oncology Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 23 Global Personalized Oncology Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 24 Global Personalized Oncology Market Outlook, By Research Institutes (2024-2032) ($MN)
  • Table 25 Global Personalized Oncology Market Outlook, By Pharmacies & Retail (2024-2032) ($MN)
  • Table 26 Global Personalized Oncology Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.